

Hyun Cheol Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2836048/publications.pdf>

Version: 2024-02-01

365
papers

23,857
citations

30551

56
h-index

11282

141
g-index

368
all docs

368
docs citations

368
times ranked

24344
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2461-2471. | 6.3 | 1,749 |
| 2 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10. | 0.8 | 1,740 |
| 3 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet, The</i> , 2012, 379, 315-321. | 6.3 | 1,422 |
| 4 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology, The</i> , 2020, 21, 1353-1365. | 5.1 | 1,363 |
| 5 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018, 392, 123-133. | 6.3 | 984 |
| 6 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , 2016, 17, 717-726. | 5.1 | 943 |
| 7 | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1389-1396. | 5.1 | 849 |
| 8 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 859-870. | 5.1 | 699 |
| 9 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478. | 0.8 | 671 |
| 10 | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. <i>Nature Medicine</i> , 2013, 19, 329-336. | 15.2 | 634 |
| 11 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571. | 3.4 | 611 |
| 12 | Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN-A Randomized, Phase III Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2039-2049. | 0.8 | 524 |
| 13 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 241-250. | 1.1 | 472 |
| 14 | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , 2017, 18, 640-653. | 5.1 | 383 |
| 15 | Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. <i>PLoS Genetics</i> , 2009, 5, e1000676. | 1.5 | 354 |
| 16 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730. | 18.7 | 335 |
| 17 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159. | 2.9 | 329 |
| 18 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198. | 2.3 | 288 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247. | 5.1 | 268 |
| 20 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 618-627. | 0.5 | 254 |
| 21 | Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731. | 6.1 | 197 |
| 22 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837. | 2.7 | 181 |
| 23 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 319-328. | 1.2 | 160 |
| 24 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519. | 2.7 | 155 |
| 25 | Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 498-507. | 1.2 | 139 |
| 26 | Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8506-8506. | 0.8 | 131 |
| 27 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434. | 1.1 | 124 |
| 28 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359. | 1.8 | 122 |
| 29 | Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4007-LBA4007. | 0.8 | 119 |
| 30 | Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953. | 2.1 | 117 |
| 31 | First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501. | 1.1 | 117 |
| 32 | A randomized phase II trial of S-1-oxaliplatin versus capecitabine+oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012, 48, 518-526. | 1.3 | 116 |
| 33 | Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012, 13, 348. | 1.2 | 114 |
| 34 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992. | 3.2 | 107 |
| 35 | Inhibition of Gastric Cancer Invasion and Metastasis by <i>PLA2G2A</i> , a Novel β -Catenin/TCF Target Gene. <i>Cancer Research</i> , 2008, 68, 4277-4286. | 0.4 | 103 |
| 36 | Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut</i> , 2021, 70, 829-837. | 6.1 | 94 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. Journal of Clinical Oncology, 2019, 37, 4079-4079. | 0.8 | 94 |
| 38 | Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer, 2017, 17, 283. | 1.1 | 93 |
| 39 | AMPK \pm Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Cancer Research, 2012, 72, 2512-2521. | 0.4 | 91 |
| 40 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2020, 26, 846-854. | 3.2 | 90 |
| 41 | Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. Journal of Surgical Oncology, 2007, 95, 461-468. | 0.8 | 89 |
| 42 | Activation of Hypoxia-Inducible Factor-1 α Is Necessary for Lysophosphatidic Acid α -Induced Vascular Endothelial Growth Factor Expression. Clinical Cancer Research, 2006, 12, 6351-6358. | 3.2 | 85 |
| 43 | Prediction of Recurrence of Early Gastric Cancer After Curative Resection. Annals of Surgical Oncology, 2009, 16, 1896-1902. | 0.7 | 84 |
| 44 | Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clinical Epigenetics, 2017, 9, 126. | 1.8 | 82 |
| 45 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235. | 3.4 | 74 |
| 46 | Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. Annals of Surgical Oncology, 2007, 14, 2730-2737. | 0.7 | 72 |
| 47 | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007. | 0.6 | 72 |
| 48 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. Annals of Surgical Oncology, 2018, 25, 3222-3230. | 0.7 | 69 |
| 49 | Avelumab (anti α -PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30. | | 68 |
| 50 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 2017, 81, 17-25. | 1.3 | 64 |
| 51 | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164. | 1.1 | 64 |
| 52 | Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. Journal of Clinical Oncology, 2017, 35, 2-2. | 0.8 | 64 |
| 53 | Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Letters, 2004, 214, 215-224. | 3.2 | 63 |
| 54 | Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Research and Treatment, 2005, 90, 215-221. | 1.1 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67. | 1.3 | 63 |
| 56 | High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. , 1997, 79, 878-883. | | 61 |
| 57 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958. | 2.7 | 61 |
| 58 | A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 204-210. | 0.4 | 60 |
| 59 | Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5514-5514. | 0.8 | 60 |
| 60 | Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5522-5522. | 0.8 | 59 |
| 61 | Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3-3. | 0.8 | 58 |
| 62 | Standardization of the Korean version of Mini-Mental Adjustment to Cancer (Mini-MAC) scale: factor structure, reliability and validity. <i>Psycho-Oncology</i> , 2008, 17, 592-597. | 1.0 | 57 |
| 63 | Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016, 263, 96-102. | 2.1 | 56 |
| 64 | KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4012-4012. | 0.8 | 55 |
| 65 | Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , 2007, 89, 451-459. | 1.3 | 54 |
| 66 | <i>CD44-SLC1A2</i> Gene Fusions in Gastric Cancer. <i>Science Translational Medicine</i> , 2011, 3, 77ra30. | 5.8 | 54 |
| 67 | A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2414-2423. | 3.2 | 54 |
| 68 | Intermediate Dose 5-Fluorouracil-Induced Encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 55-59. | 0.6 | 53 |
| 69 | Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931. | 3.2 | 53 |
| 70 | Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 429-438. | 0.7 | 52 |
| 71 | The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 275-280. | 0.8 | 52 |
| 72 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556. | 0.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1116. | 1.1 | 51 |
| 74 | Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 224-231. | 0.7 | 50 |
| 75 | An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients. <i>Oncologist</i> , 2007, 12, 622-630. | 1.9 | 48 |
| 76 | Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 55-63. | 1.1 | 48 |
| 77 | Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405. | 0.9 | 48 |
| 78 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776. | 1.7 | 48 |
| 79 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death Ligand 1 Blockade Responses. <i>Hepatology</i> , 2021, 74, 1914-1931. | 3.6 | 48 |
| 80 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016, 7, 44608-44620. | 0.8 | 46 |
| 81 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , 2021, 22, 1740-1751. | 5.1 | 46 |
| 82 | Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. <i>Journal of Clinical Oncology</i> , 1997, 15, 462-467. | | 45 |
| 83 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153. | 2.7 | 45 |
| 84 | PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , 2016, 1, e87607. | 2.3 | 44 |
| 85 | The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. <i>Annals of Surgical Oncology</i> , 2010, 17, 3259-3268. | 0.7 | 43 |
| 86 | LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. <i>Journal of Clinical Oncology</i> , 2021, 39, 94-94. | 0.8 | 43 |
| 87 | Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. <i>International Journal of Cancer</i> , 2005, 114, 484-489. | 2.3 | 42 |
| 88 | Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. <i>International Journal of Hyperthermia</i> , 2010, 26, 305-315. | 1.1 | 42 |
| 89 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011, 117, 2050-2057. | 2.0 | 42 |
| 90 | A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. <i>PLoS Genetics</i> , 2011, 7, e1002415. | 1.5 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066. | 0.8 | 42 |
| 92 | Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , 1996, 14, 512-519. | 1.7 | 41 |
| 93 | FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study. <i>Psychoneuroendocrinology</i> , 2012, 37, 1569-1576. | 1.3 | 40 |
| 94 | Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 98-104. | 1.5 | 39 |
| 95 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056. | 5.1 | 39 |
| 96 | Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 175-181. | 1.1 | 38 |
| 97 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 65-72. | 1.1 | 38 |
| 98 | Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 1033-1040. | 1.8 | 38 |
| 99 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759. | 1.0 | 38 |
| 100 | Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. <i>Experimental and Molecular Pathology</i> , 2016, 100, 287-293. | 0.9 | 38 |
| 101 | HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 228-238. | 1.9 | 38 |
| 102 | Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 587-601. | 2.0 | 38 |
| 103 | The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537. | 0.8 | 38 |
| 104 | Prevalence and associated factors of psychological distress among Korean cancer patients. <i>General Hospital Psychiatry</i> , 2011, 33, 246-252. | 1.2 | 37 |
| 105 | A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. <i>Oncology</i> , 2011, 80, 142-150. | 0.9 | 36 |
| 106 | Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. <i>BMC Cancer</i> , 2013, 13, 394. | 1.1 | 35 |
| 107 | The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3074-3085. | 1.9 | 35 |
| 108 | Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498. | 3.2 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010, 288, 124-132. | 3.2 | 34 |
| 110 | Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 321-321. | 0.8 | 34 |
| 111 | PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501. | 0.8 | 34 |
| 112 | Multi-Institutional Phase II Study of Sâ€1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. <i>Oncologist</i> , 2007, 12, 543-554. | 1.9 | 33 |
| 113 | Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 487-492. | 0.6 | 33 |
| 114 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6012-6012. | 0.8 | 33 |
| 115 | The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224. | 2.7 | 32 |
| 116 | A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 | 0.8 | 31 |
| 117 | Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4503-4503. | 0.8 | 31 |
| 118 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain. <i>Oncology</i> , 1996, 53, 192-197. | 0.9 | 30 |
| 119 | Cyclic Induction of Senescence with Intermittent AZT Treatment Accelerates both Apoptosis and Telomere Loss. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 227-236. | 1.1 | 30 |
| 120 | Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. <i>BMC Genomics</i> , 2007, 8, 305. | 1.2 | 30 |
| 121 | Gastrointestinal Stromal Tumor of the Rectum: An Analysis of Seven Cases. <i>Surgery Today</i> , 2007, 37, 455-459. | 0.7 | 30 |
| 122 | High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014, 12, 232. | 0.8 | 30 |
| 123 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1123-1130. | 1.2 | 29 |
| 124 | Gastric Cancer in Young Patients Who Underwent Curative Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 45-48. | 0.6 | 29 |
| 125 | Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites. <i>Cancer Research and Treatment</i> , 2010, 42, 217. | 1.3 | 29 |
| 126 | Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26. | 2.9 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Angiogenic Factor Thymidine Phosphorylase Increases Cancer Cell Invasion Activity in Patients with Gastric Adenocarcinoma. <i>Molecular Cancer Research</i> , 2008, 6, 1554-1566. | 1.5 | 27 |
| 128 | Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003. | 0.6 | 27 |
| 129 | PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 76-85. | 0.9 | 27 |
| 130 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207. | 1.1 | 27 |
| 131 | Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 167-167. | 0.8 | 27 |
| 132 | Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , 2022, 128, 995-1003. | 2.0 | 27 |
| 133 | Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1901-1913. | 1.2 | 26 |
| 134 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307. | 0.3 | 26 |
| 135 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268. | | 26 |
| 136 | A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1039-1039. | 0.8 | 26 |
| 137 | The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512. | 0.8 | 26 |
| 138 | Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma¹. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 475-479. | 1.4 | 25 |
| 139 | The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 517-526. | 1.2 | 25 |
| 140 | Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243. | 2.8 | 25 |
| 141 | Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6010-6010. | 0.8 | 25 |
| 142 | Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196. | 1.3 | 25 |
| 143 | Perioperative Blood Transfusions and Prognosis in Patients with Curatively Resected Locally Advanced Gastric Cancer. <i>Oncology</i> , 1995, 52, 170-175. | 0.9 | 24 |
| 144 | Forty-nine gastric cancer cell lines with integrative genomic profiling for development of a MET inhibitor. <i>International Journal of Cancer</i> , 2018, 143, 151-159. | 2.3 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3202-3210. | 3.2 | 24 |
| 146 | Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50 Oncology, 2020, 38, 3081-3081. | 0.8 | 24 |
| 147 | Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , 1998, 39, 27. | 0.9 | 23 |
| 148 | Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , 2000, 150, 137-145. | 3.2 | 23 |
| 149 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805. | 1.1 | 23 |
| 150 | Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , 2005, 11, 79-86. | 3.2 | 23 |
| 151 | Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. <i>International Journal of Oncology</i> , 2003, 22, 741. | 1.4 | 22 |
| 152 | Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 1091. | 2.3 | 22 |
| 153 | Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010, 101, 2200-2206. | 1.7 | 22 |
| 154 | High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. <i>Oncology Letters</i> , 2012, 4, 123-130. | 0.8 | 22 |
| 155 | Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , 2014, 46, 316-324. | 0.3 | 22 |
| 156 | Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanamide, a novel histone deacetylase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 233-238. | 1.0 | 21 |
| 157 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010, 28, 650-658. | 1.2 | 21 |
| 158 | Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277. | 3.2 | 21 |
| 159 | The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. <i>Yonsei Medical Journal</i> , 1992, 33, 137. | 0.9 | 20 |
| 160 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 672-680. | 1.2 | 20 |
| 161 | Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013, 107, 613-618. | 0.8 | 20 |
| 162 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281. | 3.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. Journal of Clinical Oncology, 2014, 32, 2514-2514. | 0.8 | 20 |
| 164 | Relationship between p53 Overexpression and Gastric Cancer Progression. Oncology, 1997, 54, 166-170. | 0.9 | 19 |
| 165 | Early Postoperative Intraperitoneal Chemotherapy with Mitomycin C, 5-Fluorouracil and Cisplatin for Advanced Gastric Cancer. Oncology, 2001, 60, 24-30. | 0.9 | 19 |
| 166 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer, 2019, 22, 1153-1163. | 2.7 | 19 |
| 167 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 315-321. | 1.1 | 18 |
| 168 | A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scandinavian Journal of Gastroenterology, 2010, 45, 217-225. | 0.6 | 18 |
| 169 | Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Supportive Care in Cancer, 2012, 20, 2177-2182. | 1.0 | 18 |
| 170 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf treated with chemotherapy. Investigational New Drugs, 2012, 30, 1501-1510. | 1.2 | 18 |
| 171 | Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Annals of Surgical Oncology, 2013, 20, 2615-2624. | 0.7 | 18 |
| 172 | Prognosis of pN3 Stage Gastric Cancer. Cancer Research and Treatment, 2009, 41, 73. | 1.3 | 18 |
| 173 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Research and Treatment, 2019, 51, 1-11. | 1.3 | 17 |
| 174 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Investigational New Drugs, 2021, 39, 1366-1374. | 1.2 | 17 |
| 175 | KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. Journal of Clinical Oncology, 2019, 37, TPS4146-TPS4146. | 0.8 | 17 |
| 176 | Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Cancer Letters, 1997, 118, 37-46. | 3.2 | 16 |
| 177 | In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics, 2009, 93, 52-61. | 1.3 | 16 |
| 178 | Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncology Reports, 2011, 25, 717-27. | 1.2 | 16 |
| 179 | Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?. Medicine (United States), 2015, 94, e1259. | 0.4 | 16 |
| 180 | Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Annals of Nuclear Medicine, 2016, 30, 279-286. | 1.2 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 61837-61845. | 0.8 | 16 |
| 182 | MET in gastric cancer with liver metastasis: The relationship between <i>MET</i> amplification and Met overexpression in primary stomach tumors and liver metastasis. <i>Journal of Surgical Oncology</i> , 2018, 117, 1679-1686. | 0.8 | 16 |
| 183 | Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018, 18, 158. | 1.1 | 16 |
| 184 | Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 84-91. | 1.4 | 16 |
| 185 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 49-60. | 1.3 | 16 |
| 186 | Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 323-329. | 1.3 | 16 |
| 187 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. <i>Targeted Oncology</i> , 2021, 16, 447-459. | 1.7 | 16 |
| 188 | MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252. | 0.8 | 16 |
| 189 | Pregnancy-Associated Osteoporosis. <i>Yonsei Medical Journal</i> , 1988, 29, 286. | 0.9 | 15 |
| 190 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 41-50. | 1.1 | 15 |
| 191 | Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1857-1864. | 0.6 | 15 |
| 192 | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. <i>Oncology</i> , 2006, 70, 63-70. | 0.9 | 15 |
| 193 | Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. <i>Journal of Psychosomatic Research</i> , 2014, 77, 76-80. | 1.2 | 15 |
| 194 | Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. <i>Oncology</i> , 2015, 88, 147-156. | 0.9 | 15 |
| 195 | Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6171-6180. | 0.5 | 15 |
| 196 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1108-e1114. | 1.9 | 15 |
| 197 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> . 2021. 189. 665-676. | 1.1 | 15 |
| 198 | A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2514-2514. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS ONE, 2012, 7, e45127. | 1.1 | 15 |
| 200 | Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. BMC Bioinformatics, 2008, 9, 283. | 1.2 | 14 |
| 201 | Subtelomeric DNA methylation and telomere length in human cancer cells. Cancer Letters, 2009, 281, 82-91. | 3.2 | 14 |
| 202 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 801-810. | 0.7 | 14 |
| 203 | Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. Japanese Journal of Clinical Oncology, 2011, 41, 1344-1350. | 0.6 | 14 |
| 204 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. Oncology, 2019, 96, 59-69. | 0.9 | 14 |
| 205 | Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. Journal of Clinical Oncology, 2019, 37, 4009-4009. | 0.8 | 14 |
| 206 | Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 851-860. | 1.3 | 14 |
| 207 | Severe Hypothyroidism Induced by Thyroid Metastasis of Colon Adenocarcinoma: A Case Report and Review of the Literature. Endocrine Journal, 2006, 53, 339-343. | 0.7 | 13 |
| 208 | Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 157-165. | 1.1 | 13 |
| 209 | G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Letters, 2009, 277, 155-163. | 3.2 | 13 |
| 210 | The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3938-3945. | 0.7 | 13 |
| 211 | A novel <i>TP53-KPNA3</i> translocation defines a de novo treatment-resistant clone in osteosarcoma. Journal of Physical Education and Sports Management, 2016, 2, a000992. | 0.5 | 13 |
| 212 | A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 569-572. | 0.6 | 13 |
| 213 | Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1 ⁺ positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. Journal of Clinical Oncology, 2020, 38, 427-427. | 0.8 | 13 |
| 214 | Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 2017, 8, 31169-31179. | 0.8 | 13 |
| 215 | Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. Cancer Research and Treatment, 1970, 47, 9-17. | 1.3 | 12 |
| 216 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2008, 62, 263-270. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. <i>BMC Cancer</i> , 2008, 8, 8. | 1.1 | 12 |
| 218 | High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059. | 1.2 | 12 |
| 219 | Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 484-489. | 0.6 | 12 |
| 220 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222. | 1.3 | 12 |
| 221 | Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. <i>Cancer Gene Therapy</i> , 2004, 11, 532-538. | 2.2 | 11 |
| 222 | A Pilot Study of Trans-Arterial Injection of ¹⁶⁶ Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2005, 46, 799. | 0.9 | 11 |
| 223 | Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast. <i>Human Pathology</i> , 2009, 40, 98-107. | 1.1 | 11 |
| 224 | Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. <i>Journal of Surgical Oncology</i> , 2010, 102, 454-461. | 0.8 | 11 |
| 225 | Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013, 31, 1-13. | 1.2 | 11 |
| 226 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013, 54, 52-60. | 0.8 | 11 |
| 227 | <i>PINCH</i> presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015, 136, 2273-2283. | 2.3 | 11 |
| 228 | Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study. <i>Supportive Care in Cancer</i> , 2020, 28, 1265-1275. | 1.0 | 11 |
| 229 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , 2021, 183, 114320. | 2.0 | 11 |
| 230 | Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4031-4031. | 0.8 | 11 |
| 231 | A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3056-3056. | 0.8 | 11 |
| 232 | Male breast cancer: a 20-year review of 16 cases at Yonsei University. <i>Yonsei Medical Journal</i> , 1990, 31, 242. | 0.9 | 10 |
| 233 | Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , 2007, 8, 218. | 1.2 | 10 |
| 234 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81. | 1.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Variation of the 3â€² telomeric overhang lengths in human cells. <i>Cancer Letters</i> , 2008, 264, 107-118. | 3.2 | 10 |
| 236 | Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021, 10, 3249-3260. | 1.3 | 10 |
| 237 | Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4062-4062. | 0.8 | 10 |
| 238 | First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4534-4534. | 0.8 | 10 |
| 239 | A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 383-383. | 0.8 | 10 |
| 240 | Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015, 47, 781-789. | 1.3 | 10 |
| 241 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831. | 1.3 | 10 |
| 242 | Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 72-86. | 1.4 | 10 |
| 243 | Comparison of adjuvant radiotherapy and chemoradiotherapy following surgery in stage IE and IIE primary gastrointestinal tract non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1990, 31, 144. | 0.9 | 9 |
| 244 | The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. <i>Cancer</i> , 2001, 91, 2343-2352. | 2.0 | 9 |
| 245 | The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. <i>International Journal of Molecular Medicine</i> , 2004, 13, 17. | 1.8 | 9 |
| 246 | Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 258-269. | 0.7 | 9 |
| 247 | Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , 2013, 31, 1202-1208. | 1.8 | 9 |
| 248 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. <i>Biochemical Pharmacology</i> , 2017, 138, 163-173. | 2.0 | 9 |
| 249 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217. | 2.7 | 9 |
| 250 | Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4523-4523. | 0.8 | 9 |
| 251 | An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions. <i>Cancer Research and Treatment</i> , 2007, 39, 74. | 1.3 | 9 |
| 252 | Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers.. <i>Journal of Korean Medical Science</i> , 1992, 7, 110. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. <i>Yonsei Medical Journal</i> , 1991, 32, 126. | 0.9 | 6 |
| 272 | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008, 270, 269-276. | 3.2 | 6 |
| 273 | Novel biomarker candidates for gastric cancer. <i>Oncology Reports</i> , 2008, , . | 1.2 | 6 |
| 274 | Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening. <i>Yonsei Medical Journal</i> , 2009, 50, 331. | 0.9 | 6 |
| 275 | A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. <i>Oncology</i> , 2009, 77, 349-357. | 0.9 | 6 |
| 276 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 919-927. | 1.1 | 6 |
| 277 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. <i>BMC Cancer</i> , 2013, 13, 583. | 1.1 | 6 |
| 278 | Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2385-2392. | 0.8 | 6 |
| 279 | Regulation of proliferation and invasion by the <sc>IGF</sc> signalling pathway in Epsteinâ€Barr virusâ€positive gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5899-5908. | 1.6 | 6 |
| 280 | Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10565-10565. | 0.8 | 6 |
| 281 | Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4036-4036. | 0.8 | 6 |
| 282 | ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3145-TPS3145. | 0.8 | 6 |
| 283 | Prognostic significance of Tâ€inflamed gene expression profile and PDâ€1 expression in patients with esophageal cancer. <i>Cancer Medicine</i> , 2021, 10, 8365-8376. | 1.3 | 6 |
| 284 | Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4540-4540. | 0.8 | 6 |
| 285 | Pleural Aspergillosis. <i>Yonsei Medical Journal</i> , 1988, 29, 84. | 0.9 | 5 |
| 286 | P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer. <i>Yonsei Medical Journal</i> , 1996, 37, 397. | 0.9 | 5 |
| 287 | Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. <i>International Journal of Molecular Medicine</i> , 2005, 16, 857. | 1.8 | 5 |
| 288 | Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. <i>Investigational New Drugs</i> , 2014, 32, 753-761. | 1.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- β 2) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16505-e16505. | 0.8 | 5 |
| 290 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1578-1588. | 1.3 | 5 |
| 291 | Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 712-712. | 0.8 | 5 |
| 292 | Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. <i>Oncology Reports</i> , 2007, , . | 1.2 | 4 |
| 293 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999. | 1.1 | 4 |
| 294 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 773-781. | 1.2 | 4 |
| 295 | Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS264-TPS264. | 0.8 | 4 |
| 296 | MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4134-TPS4134. | 0.8 | 4 |
| 297 | KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS463-TPS463. | 0.8 | 4 |
| 298 | A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report. <i>Cancer Research and Treatment</i> , 2007, 39, 134. | 1.3 | 4 |
| 299 | Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. <i>Hepato-Gastroenterology</i> , 2012, 59, 1313-8. | 0.5 | 4 |
| 300 | Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. <i>Yonsei Medical Journal</i> , 1990, 31, 74. | 0.9 | 3 |
| 301 | An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1998, 39, 463. | 0.9 | 3 |
| 302 | Systematic analysis of cDNA microarray-based CGH. <i>International Journal of Molecular Medicine</i> , 2006, 17, 261. | 1.8 | 3 |
| 303 | Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. <i>Oncology Reports</i> , 2006, 15, 749. | 1.2 | 3 |
| 304 | Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction. <i>Yonsei Medical Journal</i> , 2009, 50, 296. | 0.9 | 3 |
| 305 | Identification of significant regional genetic variations using continuous CNV values in aCGH data. <i>Genomics</i> , 2009, 94, 317-323. | 1.3 | 3 |
| 306 | A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 56-60. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 141-143. | 0.7 | 3 |
| 308 | Inflammatory and Tumor Stimulating Responses after Laparoscopic Sigmoidectomy. <i>Yonsei Medical Journal</i> , 2011, 52, 635. | 0.9 | 3 |
| 309 | ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. <i>Biochemical Pharmacology</i> , 2017, 123, 73-84. | 2.0 | 3 |
| 310 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 255-262. | 1.1 | 3 |
| 311 | Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8. | 0.8 | 3 |
| 312 | Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1-“positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16586-e16586. | 0.8 | 3 |
| 313 | T-cell-“inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 26-26. | 0.8 | 3 |
| 314 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. <i>Genomics and Informatics</i> , 2020, 18, e37. | 0.4 | 3 |
| 315 | Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1387-1403. | 2.1 | 3 |
| 316 | Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. <i>International Journal of Molecular Medicine</i> , 2002, 10, 251. | 1.8 | 2 |
| 317 | Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 31-37. | 1.1 | 2 |
| 318 | Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. <i>International Journal of Oncology</i> , 2009, 34, 837-46. | 1.4 | 2 |
| 319 | Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1501-1512. | 1.2 | 2 |
| 320 | Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 29-35. | 0.6 | 2 |
| 321 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 561-568. | 1.2 | 2 |
| 322 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28. | 1.3 | 2 |
| 323 | High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. , 1997, 79, 878. | | 2 |
| 324 | Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS468-TPS468. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. <i>International Journal of Molecular Medicine</i> , 2007, 19, 901-8. | 1.8 | 2 |
| 326 | Should all the N3 lymph nodes group metastasis be regarded as distant metastasis (M1) in curatively resected gastric cancer? <i>Yonsei Medical Journal</i> , 1992, 33, 143. | 0.9 | 1 |
| 327 | Immunohistochemical Expression of c-erbB2, c-erbB3 and c-erbB4 Protein in Breast Cancer. <i>Journal of Korean Breast Cancer Society</i> , 1998, 1, 215. | 0.1 | 1 |
| 328 | Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion before and during cisplatin chemotherapy in patients with intrathoracic malignancy. <i>Tuberculosis and Respiratory Diseases</i> , 1999, 46, 811. | 0.2 | 1 |
| 329 | Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. <i>Wiley Series in Probability and Statistics</i> , 2006, , 333-343. | 0.0 | 1 |
| 330 | Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007, 46, 547-549. | 0.8 | 1 |
| 331 | Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA. <i>International Journal of Molecular Medicine</i> , 0, , . | 1.8 | 1 |
| 332 | Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009, 34, 787-96. | 1.4 | 1 |
| 333 | Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012, 12, 471. | 1.1 | 1 |
| 334 | Identification of Natural Products as Novel PI3K ^{Î²} Inhibitors Through Pharmacophore-based Virtual Screening. <i>Bulletin of the Korean Chemical Society</i> , 2018, 39, 294-299. | 1.0 | 1 |
| 335 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 562284. | 1.3 | 1 |
| 336 | Abstract 945: Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells. , 2021, , . | | 1 |
| 337 | Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 259-259. | 0.8 | 1 |
| 338 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 492-492. | 0.8 | 1 |
| 339 | An update on the randomized phase III POST trial: S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4042-4042. | 0.8 | 1 |
| 340 | Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 90-90. | 0.8 | 1 |
| 341 | Prospective validation of a serum miRNA panel for early detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4065-4065. | 0.8 | 1 |
| 342 | Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports. <i>Cancer Research and Treatment</i> , 2006, 38, 184. | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | PD-L1 expression in patients with metastatic gastric cancer in South Korea.. Journal of Clinical Oncology, 2017, 35, 1571-1571. | 0.8 | 1 |
| 344 | CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2021, 23, vi73-vi74. | 0.6 | 1 |
| 345 | Clinical and Mammographic Findings of Primary Lymphoma of the Breast. Journal of the Korean Radiological Society, 1997, 37, 177. | 0.0 | 0 |
| 346 | Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. International Journal of Molecular Medicine, 2007, 19, 901. | 1.8 | 0 |
| 347 | Prediction of S-1-induced anemia. Gastric Cancer, 2009, 12, 23-30. | 2.7 | 0 |
| 348 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Cancer Chemotherapy and Pharmacology, 2010, 66, 425-431. | 1.1 | 0 |
| 349 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. AAPS Journal, 2018, 20, 72. | 2.2 | 0 |
| 350 | Abstract 1090: Overcoming trastuzumab resistance using trastuzumab deruxtecan (T-DXd), a HER2 targeting antibody drug conjugate, in HER2 amplified gastric cancer. , 2021, , . | | 0 |
| 351 | Abstract 2055: Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer. , 2021, , . | | 0 |
| 352 | Abstract 2973: Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy. , 2021, , . | | 0 |
| 353 | S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer. Korean Journal of Internal Medicine, 2008, 23, 37. | 0.7 | 0 |
| 354 | Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.. Journal of Clinical Oncology, 2012, 30, 3606-3606. | 0.8 | 0 |
| 355 | Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14652-e14652. | 0.8 | 0 |
| 356 | Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.. Journal of Clinical Oncology, 2012, 30, e14084-e14084. | 0.8 | 0 |
| 357 | The effect of delay of adjuvant chemotherapy on survival in patients with resected stage II and III gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15144-e15144. | 0.8 | 0 |
| 358 | Clinicopathologic features predicting HER2 overexpression in gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15098-e15098. | 0.8 | 0 |
| 359 | Role of Mammography in Evaluating Residual Cancer after Neo-adjuvant Chemotherapy of Locally Advanced Breast Carcinoma: Compared with Clinical Examination. Journal of the Korean Radiological Society, 1997, 36, 1081. | 0.0 | 0 |
| 360 | MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. Journal of Clinical Oncology, 2014, 32, e22164-e22164. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15020-e15020. | 0.8 | 0 |
| 362 | Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. Journal of Clinical Oncology, 2015, 33, 11010-11010. | 0.8 | 0 |
| 363 | Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113. | 0.8 | 0 |
| 364 | Waun Ki Hong, MD, D.M.Sc (Hon) (1942â€“2019): A Mentor Who Left Behind a Legacy for Generations to Come. Yonsei Medical Journal, 2020, 61, 557. | 0.9 | 0 |
| 365 | 409â€“...Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. , 2021, 9, A440-A440. | | 0 |